Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 226

1.

Challenges to licensure of enterovirus 71 vaccines.

Lee MS, Tseng FC, Wang JR, Chi CY, Chong P, Su IJ.

PLoS Negl Trop Dis. 2012;6(8):e1737. doi: 10.1371/journal.pntd.0001737. Epub 2012 Aug 28. Review.

2.

A novel inactivated enterovirus 71 vaccine can elicit cross-protective immunity against coxsackievirus A16 in mice.

Yang L, Liu Y, Li S, Zhao H, Lin Q, Yu H, Huang X, Zheng Q, Cheng T, Xia N.

Vaccine. 2016 Nov 21;34(48):5938-5945. doi: 10.1016/j.vaccine.2016.10.018. Epub 2016 Oct 19.

PMID:
27771182
3.

A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice.

Ku Z, Liu Q, Ye X, Cai Y, Wang X, Shi J, Li D, Jin X, An W, Huang Z.

Vaccine. 2014 Jul 23;32(34):4296-303. doi: 10.1016/j.vaccine.2014.06.025. Epub 2014 Jun 17.

PMID:
24950363
4.

EV71: an emerging infectious disease vaccine target in the Far East?

Xu J, Qian Y, Wang S, Serrano JM, Li W, Huang Z, Lu S.

Vaccine. 2010 Apr 30;28(20):3516-21. doi: 10.1016/j.vaccine.2010.03.003. Epub 2010 Mar 19. Review.

PMID:
20304038
5.

A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses.

Cai Y, Ku Z, Liu Q, Leng Q, Huang Z.

Vaccine. 2014 May 1;32(21):2406-12. doi: 10.1016/j.vaccine.2014.03.012. Epub 2014 Mar 18.

PMID:
24657161
6.

Enterovirus 71 vaccine: close but still far.

Zhang D, Lu J, Lu J.

Int J Infect Dis. 2010 Sep;14(9):e739-43. doi: 10.1016/j.ijid.2009.12.002. Epub 2010 Apr 18. Review.

7.

EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases.

Mao Q, Wang Y, Bian L, Xu M, Liang Z.

Emerg Microbes Infect. 2016 Jul 20;5(7):e75. doi: 10.1038/emi.2016.73. Review.

8.

EV71 vaccines: a first step towards multivalent hand, foot and mouth disease vaccines.

Klein MH.

Expert Rev Vaccines. 2015 Mar;14(3):337-40. doi: 10.1586/14760584.2015.993385. Epub 2014 Dec 24.

PMID:
25536888
9.

2-Year Efficacy, Immunogenicity, and Safety of Vigoo Enterovirus 71 Vaccine in Healthy Chinese Children: A Randomized Open-Label Study.

Wei M, Meng F, Wang S, Li J, Zhang Y, Mao Q, Hu Y, Liu P, Shi N, Tao H, Chu K, Wang Y, Liang Z, Li X, Zhu F.

J Infect Dis. 2017 Jan 1;215(1):56-63. doi: 10.1093/infdis/jiw502. Epub 2016 Oct 17.

PMID:
28077584
10.

Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice.

Sun S, Jiang L, Liang Z, Mao Q, Su W, Zhang H, Li X, Jin J, Xu L, Zhao D, Fan P, An D, Yang P, Lu J, Lv X, Sun B, Xu F, Kong W, Jiang C.

Hum Vaccin Immunother. 2014;10(10):2885-95. doi: 10.4161/hv.29823.

11.

Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases.

Liu CC, Chow YH, Chong P, Klein M.

Vaccine. 2014 Oct 29;32(47):6177-82. doi: 10.1016/j.vaccine.2014.08.064. Epub 2014 Sep 13. Review.

PMID:
25218294
13.

Coxsackievirus A 16 infection does not interfere with the specific immune response induced by an enterovirus 71 inactivated vaccine in rhesus monkeys.

Wang J, Qi S, Zhang X, Zhang Y, Liu L, Che Y, He Z, Zhao Y, Lu S, Yu W, Li Q.

Vaccine. 2014 Jul 31;32(35):4436-42. doi: 10.1016/j.vaccine.2014.06.062. Epub 2014 Jun 21.

PMID:
24958699
14.

The compatibility of inactivated-Enterovirus 71 vaccination with Coxsackievirus A16 and Poliovirus immunizations in humans and animals.

Mao Q, Wang Y, Shao J, Ying Z, Gao F, Yao X, Li C, Ye Q, Xu M, Li R, Zhu F, Liang Z.

Hum Vaccin Immunother. 2015;11(11):2723-33. doi: 10.1080/21645515.2015.1011975. Epub 2015 Feb 25.

15.

EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD).

Mao QY, Wang Y, Bian L, Xu M, Liang Z.

Expert Rev Vaccines. 2016 May;15(5):599-606. doi: 10.1586/14760584.2016.1138862. Epub 2016 Jan 14. Review.

PMID:
26732723
16.

Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, Zhang YT, Yao X, Chu K, Chen QH, Hu YM, Wu X, Liu P, Zhu LY, Gao F, Jin H, Chen YJ, Dong YY, Liang YC, Shi NM, Ge HM, Liu L, Chen SG, Ai X, Zhang ZY, Ji YG, Luo FJ, Chen XQ, Zhang Y, Zhu LW, Liang ZL, Shen XL.

Lancet. 2013 Jun 8;381(9882):2024-32. doi: 10.1016/S0140-6736(13)61049-1. Epub 2013 May 29.

PMID:
23726161
17.

Considerations for developing an immunization strategy with enterovirus 71 vaccine.

Li L, Yin H, An Z, Feng Z.

Vaccine. 2015 Feb 25;33(9):1107-12. doi: 10.1016/j.vaccine.2014.10.081. Epub 2014 Nov 8. Review.

18.

Enterovirus 71: a whole virion inactivated enterovirus 71 vaccine.

Zhou Y, Li JX, Jin PF, Wang YX, Zhu FC.

Expert Rev Vaccines. 2016 Jul;15(7):803-13. doi: 10.1080/14760584.2016.1191357. Epub 2016 Jun 6. Review.

PMID:
27206811
19.

Review of enterovirus 71 vaccines.

Chong P, Liu CC, Chow YH, Chou AH, Klein M.

Clin Infect Dis. 2015 Mar 1;60(5):797-803. doi: 10.1093/cid/ciu852. Epub 2014 Oct 28. Review.

PMID:
25352588
20.

Structure, Immunogenicity, and Protective Mechanism of an Engineered Enterovirus 71-Like Particle Vaccine Mimicking 80S Empty Capsid.

Wang X, Ku Z, Zhang X, Ye X, Chen J, Liu Q, Zhang W, Zhang C, Fu Z, Jin X, Cong Y, Huang Z.

J Virol. 2017 Dec 14;92(1). pii: e01330-17. doi: 10.1128/JVI.01330-17. Print 2018 Jan 1.

PMID:
29070691

Supplemental Content

Support Center